More recently, new drugs have been approved for the treatment of patients with CLL, including novel CD20-targeting antibody obinutuzumab, PI3-kinase inhibitor idelalisib, and irreversible inhibitor of Bruton tyrosine kinase ibrutinib [46]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.